GLP-1 (glucagon-like peptide-1) receptor agonists have gained popularity as an effective treatment for weight loss and diabetes management
Regulatory note: Both peptides are not FDA-approved and are prohibited by WADA at all times (class S2) for athletic use [6]
Our experts consider essential factors like body mass index (BMI), existing or previous health issues (if applicable), dietary or exercise restrictions, and other relevant aspects
0 mg, orlistat, phenterminetopiramate, and naltrexonebupropion for weight loss efficacy Pharmacokinetic Profile Route of Administration SC Dosing Frequency Once weekly Half-Life 184 hours Route of Administration : Subcutaneous Dosing Frequency : Once weekly (subcutaneous) Half-Life : ~155184 hours (6.57.7 days), supporting once-weekly SC dosing Formulation : Formulation & Handling Reconstitute in sterile water or PBS (pH ~7.4) for in vivo/in vitro use Store at 20C in aliquots to prevent freeze-thaw degradation Shelf-stable for 12 months under recommended storage condition Clinical Trial Activity References Quality & Purity This product is synthesized via solid-phase peptide synthesis (SPPS) and tested to 99% purity by HPLC with identity confirmed by mass spectrometry
Research Updates & Restocks Get notified about new compounds, batch arrivals, and COA publications
Nature 600 , 500505 (2021)
